Risk factors

Inflation, tariffs, and project execution risks now explicitly threaten profit margins on fixed-price and guaranteed maximum price contracts.

Entrada faces heavy regulatory scrutiny for its EEV-based muscular dystrophy candidates like ENTR-601-44.

Trulieve split customer privacy risks into a dedicated new risk factor while dropping ten older operational disclosures. Facility theft risks were separated from customer data privacy disclosures, clarifying distinct cybersecurity and physical security threats.

High debt and leverage risks intensified following a credit facility amendment and $905.0 million in outstanding borrowings. Public sector contracts present new compliance, funding, and termination vulnerabilities that could negatively affect margins. Chairman and CEO Kenneth D. Tuchman maintains 57% voting control, posing potential governance conflicts. Artificial intelligence implementation and fragmented regulations introduce operational and legal risks for contact center services.

Titan International faces new risks from trade tensions, Supreme Court tariff rulings, and labor relations. International sales generate about half of the company's revenue.

The company expanded disclosures regarding its Williston Basin Transactions, debt levels, and credit facility restrictions.

UFG added focus on regulatory approval for subsidiary dividends and updated its bylaws with defenses against activist or takeover situations.

HTLF integration is now underway with systems converted, but remaining benefits, cost savings, and management of expanded operations remain uncertain.

USLM updated risks to reflect regulatory uncertainty from state and federal governments impacting lime and limestone demand. The company added specific mention of new market entrants following recent lime price increases. Demand risks now cite the shift away from coal-fired utility plants and changing data center construction growth.

Energy Fuels expanded its risk disclosures around rare earth elements, new metals and alloys initiatives, and debt financing.

Profitability is improving, but future losses remain possible as Vericel funds MACI Arthro, MACI Ankle, manufacturing, and international expansion.

Veracyte expanded risks regarding recent acquisitions like the C2i transaction and divestitures like Veracyte SAS.